Wird geladen...
Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ((177)Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer
LESSONS LEARNED: Hyperfractionation of lutetium‐177 ((177)Lu)‐J591 for patients with metastatic castration‐resistant prostate cancer did not appear to have any additional advantage over the single dose (177)Lu‐J591 or fractionated two‐dose (177)Lu‐J591 therapy. Definite conclusions were challenging...
Gespeichert in:
| Veröffentlicht in: | Oncologist |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Inc.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7288642/ https://ncbi.nlm.nih.gov/pubmed/31999003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0028 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|